A plain-language review of what the published HPS literature says about asthma as a comorbidity, what the French Bichat ECMO case has added in 2026, and how asthmatic readers should approach the CDC rodent-cleanup protocol.
For most of the thirty-year history of recognised hantavirus pulmonary syndrome (HPS) in the Americas, asthma has sat just outside the centre of the clinical literature. The strongest demographic predictors of fatal outcome in published case-control studies from Argentina, Chile and the United States are older age, male sex, smoking history, and delayed presentation. Asthma has not consistently emerged as an independent risk factor — but the published HPS cohorts are small, and the statistical power to detect a moderate effect from a common comorbidity like asthma is genuinely limited.
In May 2026, the question moved back into view. The French passenger from the MV Hondius cluster who is now on extracorporeal membrane oxygenation (ECMO) at Bichat-Claude Bernard Hospital in Paris is, by background reporting from NPR, the New York Times, and the CBC, a woman in her sixties with a history of asthma and additional comorbidities. Her care team, led by Dr Xavier Lescure of Bichat's infectious disease service, has described her presentation as a severe form of Andes hantavirus pulmonary syndrome with significant lung and heart involvement. The case is the first widely-reported severe HPS case in 2026 in which asthma has been explicitly named as part of the clinical picture, which is the reason hantavirus and asthma is a question worth answering directly.
Hantavirus pulmonary syndrome is, mechanistically, a disease of the pulmonary capillary endothelium. Andes virus and Sin Nombre virus both preferentially infect the endothelial cells that line the small blood vessels of the lung. After an asymptomatic incubation of one to eight weeks, infected patients enter a flu-like prodromal phase of fever, severe myalgia and headache. The defining cardiopulmonary phase begins three to seven days later, when virus-driven endothelial dysfunction causes a rapid capillary leak: protein-rich fluid floods into the alveolar spaces, the lungs become heavy and stiff, gas exchange collapses, and cardiac output falls. The pathology is a low-pressure pulmonary oedema rather than the high-pressure oedema of acute heart failure, and that distinction matters for treatment.
The most rigorous cohort-level analysis of HPS comorbidities is the long-running Argentine Patagonia cohort. In that cohort, age over fifty and time-to-hospitalisation are the dominant predictors of mortality. Among comorbidities, hypertension and chronic kidney disease show weak associations with worse outcomes; obstructive lung disease (a category that includes COPD and severe asthma) shows a small numerical trend toward worse outcomes that has not consistently reached statistical significance.
There are three mechanistic reasons asthma could plausibly worsen HPS outcomes even in the absence of a strong epidemiological signal. First, asthma is associated with chronic low-grade airway inflammation; the acute inflammatory cascade of HPS may engage on top of a primed inflammatory baseline. Second, asthma is associated with airway smooth-muscle hyper-responsiveness; bronchoconstriction triggered by acute viral infection can impair mechanical ventilation. Third, asthma is associated with a slightly altered respiratory microbiome and a higher background rate of bacterial colonisation, which can increase the risk of secondary bacterial pneumonia in critical illness.
Asthma is heterogeneous. A well-controlled mild allergic asthmatic on a low-dose inhaled corticosteroid is in a very different physiological state from a severe steroid-dependent asthmatic with chronic airway remodelling, recurrent exacerbations, and a history of intensive-care admission. The clinical concern in HPS is concentrated at the severe-asthma end of the spectrum.
Open doors and windows for at least 30 minutes before entering any closed-up space with signs of rodent activity. This single step does more to reduce inhalation exposure than any other element of the protocol, and it is particularly valuable for asthmatic cleaners because it lowers the concentration of any disturbed aerosolised material before the first breath is taken.
A NIOSH-approved N95 respirator is the minimum face-piece for hantavirus cleanup. Most adults with well-controlled asthma tolerate an N95 without difficulty: the increase in inspiratory resistance is small, and any modest increase in work of breathing is unrelated to airway inflammation. A user-seal-check at the start of cleanup matters more than it does for non-asthmatic cleaners: cup both hands gently over the mask, inhale sharply, and feel for any leak around the edges. If you have severe or poorly controlled asthma, discuss respirator tolerance with your clinician before any planned cleanup task.
Spray any visible droppings, urine staining or nesting material with a 1:10 bleach solution or an EPA-registered disinfectant and allow at least five minutes of contact time before any wiping. Never dry-sweep or dry-vacuum a contaminated space — both actions aerosolise virus-laden particles that an N95 can reduce but not eliminate.
Place contaminated material in a kitchen-sized bag, wipe the outside of that bag with disinfectant, and place the sealed inner bag inside a heavy contractor bag. Wash hands and forearms thoroughly with soap and water after removing PPE, and launder any reusable outer clothing on a hot cycle.
For readers with severe or steroid-dependent asthma, asking another adult to perform the cleanup using full PPE is a reasonable conservative choice. It is the same logic CDC applies to pregnancy: delegation is not required, but it is the lowest-risk option when one is available.
The hantavirus incubation period is roughly one to eight weeks, with most cases declaring themselves at two to four weeks. The earliest symptoms — fever, severe muscle aches, headache, fatigue, gastrointestinal upset — overlap with many common asthma-related complaints, which is why telling your asthma clinician about a rodent exposure matters: it changes the level of suspicion and the speed of escalation if you do go on to develop respiratory symptoms. The red-flag transition is to the cardiopulmonary phase: new shortness of breath that is not relieved by your usual short-acting bronchodilator, cough, low blood pressure, or rapidly worsening fatigue. These are emergency-department symptoms in this context.
As of May 17, 2026, the MV Hondius cluster total stands at 11 cases (8 PCR-confirmed Andes virus, 2 probable, 1 inconclusive) and 3 deaths. The one explicitly reported asthmatic case is the French woman on ECMO at Bichat-Claude Bernard Hospital in Paris. All approximately 122 repatriated passengers and crew are now in WHO-recommended 42-day active monitoring across roughly 20 countries; Day 5 of that monitoring window is today. WHO and ECDC continue to assess the risk to the general public — including asthmatic readers who were not on the ship and are not in close contact with a confirmed case — as low. There are no travel restrictions related to the cluster.
→ See the live MV Hondius tracker, full timeline and global news sourcesAsthma is not on the canonical list of strong, independent risk factors for severe HPS in published case-control studies, but the published HPS cohorts are small and the statistical power to detect a moderate effect from a common comorbidity like asthma is genuinely limited. Mechanistically, asthma plausibly worsens outcomes through chronic airway inflammation, airway hyper-responsiveness during acute viral illness, and a higher background rate of bacterial colonisation that can complicate critical care.
CDC does not specifically advise asthmatic adults to avoid rodent cleanup. The standard CDC cleanup protocol — ventilation for 30 minutes before entry, wet disinfection with a 1:10 bleach solution, an N95 respirator, gloves, eye protection, and double-bagged disposal — is effective at near-eliminating hantavirus exposure during cleanup. Asthmatic readers should ensure their asthma is well-controlled before any cleanup task. For severe or steroid-dependent asthma, delegation is a reasonable conservative choice.
Most adults with well-controlled asthma tolerate an N95 respirator without difficulty. The increase in inspiratory resistance is small for a NIOSH-approved N95. A user-seal-check at the start of cleanup is important. If you have severe or poorly controlled asthma, discuss respirator tolerance with your clinician before any planned cleanup task.
Yes. Background reporting on the French passenger now on ECMO at Bichat-Claude Bernard Hospital in Paris confirms she is a woman in her sixties with a history of asthma and additional comorbidities. Her care team has described her presentation as a severe form of Andes hantavirus pulmonary syndrome with significant lung and heart involvement.
Follow the CDC protocol exactly during any rodent cleanup; do not dry-sweep or dry-vacuum any contaminated space; and seek medical evaluation early for any febrile or respiratory illness in the eight weeks following a possible exposure. Tell the triage team about both the exposure and the asthma history.